ENGLEWOOD, Colo., Sept. 19, 2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, announced it will present at the upcoming Cantor Global Healthcare Conference, which is being held September 26th-28th, 2023.
Zynex's presentation will be held in person and webcast live on September 26th at 1:35 PM ET at the InterContinental Barclay Hotel in New York, NY. You can listen to the webcast at Zynex Investor Presentation Webcast. Thomas Sandgaard, Founder and CEO, and Dan Moorhead, CFO, will be available for one-on-one meetings on September 26th and 27th.
To receive additional information, register to attend, or schedule a one-on-one meeting, email the Cantor team at This email address is being protected from spambots. You need JavaScript enabled to view it..
About Zynex, Inc.
Zynex, founded in 1996, develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for use in hospitals. For additional information, please visit: www.zynex.com.
Investor Relations Contact:
Quinn Callanan, CFA or Brian Prenoveau, CFA
MZ Group – MZ North America
This email address is being protected from spambots. You need JavaScript enabled to view it.
+949 694 9594
Last Trade: | US$7.86 |
Daily Change: | 0.04 0.51 |
Daily Volume: | 41,460 |
Market Cap: | US$249.480M |
October 24, 2024 September 04, 2024 September 03, 2024 July 25, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB